@article{e9c98a7fbc974f3abd13236280b6f3d8,
title = "Which patients benefit most from adjuvant aromatase inhibitors?: Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial",
abstract = "On average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early breast cancer. Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which aromatase inhibitors may be more or less important.",
keywords = "Aged, Antineoplastic Combined Chemotherapy Protocols, Aromatase Inhibitors, Breast Neoplasms, Chemotherapy, Adjuvant, Double-Blind Method, Drug Administration Schedule, Female, Humans, Ki-67 Antigen, Middle Aged, Nitriles, Prognosis, Receptor, Epidermal Growth Factor, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Triazoles",
author = "G Viale and Regan, {M M} and P Dell'Orto and Mastropasqua, {M G} and E Maiorano and Rasmussen, {B B} and G MacGrogan and Forbes, {J F} and Paridaens, {R J} and M Colleoni and I L{\'a}ng and B Th{\"u}rlimann and H Mouridsen and L Mauriac and Gelber, {R D} and Price, {K N} and A Goldhirsch and Gusterson, {B A} and Coates, {A S} and {BIG 1-98 Collaborative and International Breast Cancer Study Groups}",
year = "2011",
doi = "10.1093/annonc/mdq738",
language = "English",
volume = "22",
pages = "2201--7",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Elsevier Limited",
number = "10",
}